Bridging Genomics Research Between Developed and Developing Countries: The Genomic Medicine Alliance

Cooper, David Neil; Brand, Angela; Dolžan, Vita; Fortina, Paolo; Innocenti, Federico; Lee, Ming Ta Michael; Maçek, Milan; Al-Mulla, Fahd; Prainsack, Barbara; Squassina, Alessio; Vayena, Effy; Vozikis, Athanassios; Williams, Marc S.; Patrinos, George P.

doi:10.2217/pme.14.59

Cited by 23 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…85,101,102 In Thailand and Singapore, where the HLA-B*15:02 variant is common and strongly predisposes to severe skin toxicity after specific drugs, pharmacogenetic testing is common. 103–105 The Genomic Medicine Alliance (http://www.genomicmedicinealliance.org/) 106 facilitates the clinical use of pharmacogenomics and has created a database linking drugs with genes. 107 Population admixture in diverse populations must also be considered in global efforts for clinical implementation.…”

Section: Reviewmentioning

confidence: 99%

Pharmacogenomics in the clinic

Relling

Evans

2015

Nature

695

569

View full text Add to dashboard Cite

Preface After decades of discovery, inherited variation in approximately 20 genes affecting about 80 medications has been identified as actionable in the clinic. Additional somatically acquired genomic variants direct the choice of “targeted” anticancer drugs for individual patients. Current efforts that focus on the processes required to appropriately act on pharmacogenomic variability in the clinic are systematically moving pharmacogenomics from discovery to implementation as an evidenced-based strategy for improving the use of medications, thereby providing an important cornerstone for precision medicine.

show abstract

Section: Reviewmentioning

confidence: 99%

Pharmacogenomics in the clinic

Relling

Evans

2015

Nature

695

569

View full text Add to dashboard Cite

show abstract

“…Sharing strategies, data, and standards could minimize wasteful duplication and speed progress in identifying genomics-based interventions most likely to improve patient care and enhance outcomes for patients and populations. Early efforts at such collaborations include the European Association for Predictive, Preventive, and Personalised Medicine (EPMA) [9], the European Commission’s EuroBioForum and Observatory [10] and the Genomic Medicine Alliance [11,12], which have spearheaded promising projects such as the application of genome sequencing in pharmacogenomics and development of online pharmacogenomic resources. Related efforts include the International Rare Disease Research Consortium (IRDiRC), developing new diagnostic strategies and therapies for rare diseases [13]; the Global Alliance for Genomics and Health (GA4GH), promoting responsible sharing of genomic data for research [14]; and EuroGentest, drafting professional guidelines for diagnostic DNA sequencing [15].…”

Section: Introductionmentioning

confidence: 99%

Global implementation of genomic medicine: We are not alone

et al. 2015

Self Cite

View full text Add to dashboard Cite

Advances in high-throughput genomic technologies coupled with a growing number of genomic results potentially useful in clinical care have led to ground-breaking genomic medicine implementation programs in various nations. Many of these innovative programs capitalize on unique local capabilities arising from the structure of their health care systems or their cultural or political milieu, as well as from unusual burdens of disease or risk alleles. Many such programs are being conducted in relative isolation and might benefit from sharing of approaches and lessons learned in other nations. The National Human Genome Research Institute recently brought together 25 of these groups from around the world to describe and compare projects, examine the current state of implementation and desired near-term capabilities, and identify opportunities for collaboration to promote the responsible implementation of genomic medicine. The wide variety of nascent programs in diverse settings demonstrates that implementation of genomic medicine is expanding globally in varied and highly innovative ways. Opportunities for collaboration abound in the areas of evidence generation, health information technology, education, workforce development, pharmacogenomics, and policy and regulatory issues. Several international organizations that are already facilitating effective research collaborations should engage to ensure implementation proceeds collaboratively without potentially wasteful duplication. Efforts to coalesce these groups around concrete but compelling signature projects, such as global eradication of genetically-mediated drug reactions or developing a truly global genomic variant data resource across a wide number of ethnicities, would accelerate appropriate implementation of genomics to improve clinical care world-wide.

show abstract

“…Within this collaborative framework, the health economics analysis can achieve more by utilizing the model generated from similar decision models and health systems across the members. Also, several Southeast Asian Pharmacogenomics Consortium members participate in other international Genomic Medicine collaborative efforts, such as the US National Institutes of Health-led Global Genomic Medicine Collaborative (G2MC) and the Genomic Medicine Alliance (http://www.genomicmedicinealliance.org) [59], hence ensuring a global representation and impact of such pharmacogenomics research.…”

Section: Evidence Generation For Policy Implementationmentioning

confidence: 99%

Clinical Application of Pharmacogenomics: The Example of HLA-Based Drug-Induced Toxicity

Lee

Mahasirimongkol²,

Zhang

et al. 2014

Public Health Genomics

View full text Add to dashboard Cite

Pharmacogenomics is gradually becoming more and more indispensable in modern medicine. In several cases, a pharmacogenomics test may alleviate serious drug-induced adverse reactions, if it precedes drug prescription. In this article, we provide an overview of the well-established HLA-based carbamazepine- and allopurinol-induced adverse reactions, as one of the most characteristic examples of the clinical application of pharmacogenomics, highlighting its regional impact in Southeast Asian populations in preventing adverse reactions of certain drug/allele pairs. This example provides useful insights towards evidence generation for policy implementation, including economic evaluation analysis, the implementation of pharmacogenomics testing procedures and monitoring of policy effectiveness, hence serving, per se or in the context of international collaborative efforts, as a model for similar cases in several national healthcare systems worldwide.

show abstract

Bridging Genomics Research Between Developed and Developing Countries: The Genomic Medicine Alliance

Cited by 23 publications

References 28 publications

Pharmacogenomics in the clinic

Pharmacogenomics in the clinic

Global implementation of genomic medicine: We are not alone

Clinical Application of Pharmacogenomics: The Example of HLA-Based Drug-Induced Toxicity

Contact Info

Product

Resources

About